Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $58.8 million.

  • C4 Therapeutics' Cash & Equivalents fell 140.82% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year decrease of 140.82%. This contributed to the annual value of $55.5 million for FY2024, which is 5615.85% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Cash & Equivalents is $58.8 million, which was down 140.82% from $78.2 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Cash & Equivalents registered a high of $281.1 million during Q2 2021, and its lowest value of $29.8 million during Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $59.6 million (2024), whereas its average is $81.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 7962.06% in 2022, then skyrocketed by 32545.54% in 2023.
  • Over the past 5 years, C4 Therapeutics' Cash & Equivalents (Quarter) stood at $76.1 million in 2021, then crashed by 60.91% to $29.8 million in 2022, then soared by 325.46% to $126.6 million in 2023, then crashed by 56.16% to $55.5 million in 2024, then rose by 5.96% to $58.8 million in 2025.
  • Its Cash & Equivalents was $58.8 million in Q3 2025, compared to $78.2 million in Q2 2025 and $51.3 million in Q1 2025.